Point-of-Care Diagnostics for HIV Viral Load in Resource-Limited Settings
Our product must be affordable so as to not put a financial burden on the health systems of the countries that will adopt our technology. This technology will be capable of performing laboratory-grade analyses on-site, in record time, and with minimum user training.
Devise a suitable manufacturing and/or business model that may allow us to offer one test for no more than $12. This figure includes the cartridge and the reagents needed to conduct the immuno-assay.